Dosing interval is a major factor determining the quality of T cells induced by SARS-CoV-2 mRNA and adenoviral vector vaccines
by Murray, Sam et al
29th August 2025 •
comment
Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study
by Kwesi-Maliepaard, E.M et al
28th May 2025 •
comment
Spike-specific IgG4 generated post BNT162b2 mRNA vaccination is inhibitory when directly competing with functional IgG subclasses
by Jerry C. H. Tam, et al.
9th May 2025 •
comment
Estimating Population Immunity to SARS-CoV-2 by Random Sampling from Primary and Secondary Healthcare
by Sam Scott et al.
21st February 2025 •
comment
Chronogram: an R package for data curation and analysis of infection and vaccination cohort studies
by David Greenwood et al.
12th December 2024 •
comment
Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant
by Julia Stowe et al.We recently reported vaccine effectiveness (VE) estimates against symptomatic disease with the Delta (B.1.617.2) variant.(1) After a full course, VE reached 88% with the Pfizer/BioNTech BNT162b2 vaccine and 67% with the AstraZeneca ChAdOx1 AZD1222 vaccine. This provided important evidence that despite modest reductions in protection, vaccines remain effective against Delta. However, the very recent emergence of the variant and the relatively low case numbers meant that it was not possible to estimate VE against severe disease.
14th June 2021 •
comment